NEXENTIS TECHNOLOGIES INC.

NASDAQ: NXTS (Nexentis Technologies Inc.)

Kemas kini terakhir: 3 hari lalu, 1:40PM

1.79

0.04 (2.29%)

Penutupan Terdahulu 1.75
Jumlah Dagangan 4,368
Harga / Jualan (P/S) 116.20
Harga / Buku (P/B) 0.280
Julat 52 Minggu
1.70 (-5%) — 119.00 (6548%)

AISkor Stockmoo

-2.4
Pulangan di bawah kos modalnya. Pulangan atas modal meningkat. info
Daripada penilaian laporan AI Insight kami tentang pulangan dijangka berbanding risiko. info NA
Penilaian Relatif info NA
Pertumbuhan Tersirat info NA
Sejarah Penilaian info NA
Kesihatan Kewangan info NA
Trend Perolehan info NA
Nilai Pegangan info NA
Premium Risiko info NA
Penilaian Pasaran info NA
Aliran menurun sepanjang tahun lalu. Jauh di bawah paras tertinggi 52 minggu. info
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik. info
Daripada analisis teknikal AI kami terhadap carta. info NA
Corak Lilin info NA
Tiada harga sasaran terkini, jadi berdasarkan arah semakan harga sasaran. info
Sentimen Pegangan info NA
Sentimen Berita info NA
Institusi bersih -0.58% daripada saham dalam pemfailan 13F terkini: 3 pemegang menambah, 2 mengurang (suku berakhir 30 Sep 2026). info
Kedudukan jual singkat +21.3% dari 31 Aug hingga 30 Oct 2026, 1 hari untuk tutup (FINRA). info
Aktiviti Orang Dalam info NA
Persekitaran pasaran berhati-hati. info
Sektor ketinggalan berbanding pasaran.
Tonggak-tonggak sependapat, jadi skor diperkukuh.
Di bawah garis aliran jangka sederhana. info
Harga rendah berbanding purata 52 minggunya. Turun dalam tempoh 5 tahun. info
Momentum jangka pendek menurun. info
Paras sokongan dan rintangan menaik. info
Skor Akhir -2.43
Tunjuk semua

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Agricultural Inputs (US) Bercampur Bercampur
Agricultural Inputs (Global) Bercampur Bercampur
Stok Nexentis Technologies Inc. - -

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B Skor
NXTS - - - 0.280 -2.4
LVRO 35 M - - - -1.6
SEED 9 M - - - -4.3
NITO 3 M - - - 0.0
BIOX 11 M - - 0.370 -4.6

Nexentis Technologies Inc, is engaged in redefining mitochondrial drug discovery with help of its wholly owned biotechnology subsidiary, MitoCareX Bio focused on drug discovery company dedicated to developing first-in-class therapeutics for inflammatory metabolic diseases and cancer by targeting specific metabolic pathways. The company is also focused on sustainable operations in various industries such as solar projects, and oncology biotechnology.

Sektor Basic Materials
Industri Agricultural Inputs
Gaya Pelaburan Small Value

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

Institusi

Pemilikan institusi: 1.62%

Kedudukan Pemegang Saham
Bertambah 3 6,225
Berkurang 2 9,178
Baharu 3 6,225
Dijual habis 1 9,048

Pemfailan SEC 13F melalui Nasdaq, pemfailan terkini hingga 30 Sep 2026. Pemfailan tiba sehingga 45 hari selepas setiap suku.

Kedudukan Jual Singkat

Penyelesaian Saham Hari untuk tutup
30 Oct 2026 63,636 1.0
15 Oct 2026 61,274 1.0
30 Sep 2026 37,720 1.0
15 Sep 2026 39,461 2.3
31 Aug 2026 52,477 1.7
14 Aug 2026 62,682 1.1

Data jual singkat FINRA melalui Nasdaq, dilaporkan dua kali sebulan.

1 Positif 0 Negatif 1 Neutral
Tarikh Jenis Butiran
17 Nov 2026 Yahoo Finance Nexentis: MitoCareX Progresses Toward In-Vitro Evaluation Following AI-Powered Computational Screening
Further computational prioritization by MitoCareX leads to selection and ordering of molecules for planned experimental assessment Ness Ziona, Israel, , Nov. 17, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today announced that its wholly owned…
05 Nov 2026 Yahoo Finance Nexentis Announces Reverse Stock Split
Ness Ziona, Israel, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests in solar energy assets based on the RTB (Ready to Build) business model, announced that its Board of Directors has approved a…
29 Oct 2026 Yahoo Finance Nexentis: MitoCareX Completes Initial AI-Powered Computational Screening Milestone with Boltz
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”)…
26 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Advances AI-Driven Drug Discovery Initiative with Boltz, Completing Initial Computational Screening Stage
MitoCareX considers preliminary, not yet experimentally validated, computational findings encouraging for further computational analysis and experimental investigation Ness Ziona, Israel, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”) today…
12 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis
MitoCareX expands its internal bioinformatics expertise to broaden the analysis of disease biology within its computational drug-discovery activities Ness Ziona, Israel, Oct. 12, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (NASDAQ: NXTS) (“Nexentis” or the “Company”), today announced that…
07 Oct 2026 Yahoo Finance Nexentis Deploys MitoCareX Computational Drug Discovery Infrastructure on Google Cloud
Nexentis subsidiary MitoCareX has moved its computational drug discovery infrastructure to Google Cloud Platform, aiming to improve computing flexibility, scientific data management and research workflows as its discovery programs develop. Key Investor TakeawaysNexentis Technologies (NASDAQ:NXTS)…
07 Oct 2026 Yahoo Finance Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud
Deployment on Google Cloud Platform is designed to enhance computational capacity, data governance and operational flexibility as MitoCareX advances its drug discovery programs Ness Ziona, Israel, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis”…
24 Sep 2026 Yahoo Finance Nexentis: MitoCareX Strengthens Its Computational Drug Discovery Capabilities with Appointment of Prof. Dan T. Major to Scientific Advisory Board
Leading computational chemistry expert to advise MitoCareX as it expands its in silico drug-discovery capabilities Ness Ziona, Israel, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Nexentis Technologies Inc. (“Nexentis”), (NASDAQ: NXTS) (“Nexentis” or the “Company”), a drug discovery company that also invests…
23 Sep 2026 Yahoo Finance Nexentis: MitoCareX Evaluates Expanded Protein Capabilities to Enhance Flexibility and Support Future Drug Discovery
Evaluation of additional commercially available approaches for obtaining proteins is intended to enhance access to research materials, increase research flexibility and support the advancement of MitoCareX’s future in-vitro drug discovery programs Ness Ziona, Israel, Sept. 23, 2026 (GLOBE NEWSWIRE)…

Persediaan Teknikal Sederhana

Susunan aliran
Kecerunan
Kemasukan
Dagangan
Aliran menurun: harga di bawah purata bergeraknya, dan purata itu sedang menurun. Harga hampir dengan purata itu. Dagangan lebih tinggi pada hari harga naik.
Rintangan terdekat: 1.83 – 2.02 · paras sederhana

AI Analisis Teknikal

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Risiko / Ganjaran
TP1:
TP2:

Kerugian hingga SL berbanding keuntungan hingga setiap sasaran, dari EP. Nisbah 2 atau lebih biasanya dicari.

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda